Table 2 Evaluation of efficacy of neoadjuvant Aumolertinib (n = 51)
Variables | All Patients | Mutant Subtypes, No. (%) | ||
|---|---|---|---|---|
Ex19-Del | Ex21-L858R | P | ||
Median Neoadjuvant Treatment cycle (range) | 0.397 | |||
4.0 (2–6) | 4.0 (3–4) | 4.0 (3–6) | ||
Surgery Treatment | 0.445 | |||
Performed | 23 | 9 (40.9) | 14 (51.9) | |
Non-Performed | 28 | 13 (50.1) | 13 (48.1) | |
Tumor Response | 0.006 | |||
PR | 36 (70.6) | 20 (90.9) | 16 (59.3) | |
SD | 15 (29.4) | 2 (9.1) | 11 (40.7) | |
ORR (%) | 0.362 | |||
70.6 | 90.9 | 59.3 | ||
DCR (%) | / | |||
100.0 | 100.0 | 100.0 | ||
TLD Response in CT, % (range) | 0.003 | |||
37.8 (-4–86) | 45.8 (6–86) | 31.2 (0–58) | ||
PT-S Response in PET-CT, % (range)* | 0.557 | |||
64.8 (3.5–100.0) | 66.0 (3.0–100.0) | 72.3 (7.8–89.7) | ||
ypN Downstaging# | 0.190 | |||
17 (73.9) | 8 (88.9) | 9 (64.3) | ||
ypTNM# | 0.219 | |||
0/I | 13 (56.6) | 7 (77.8) | 6 (42.9) | |
II | 3 (13.0) | 1 (11.1) | 2 (14.2) | |
III | 7 (30.4) | 1 (11.1) | 6 (42.9) | |
Type of Surgery# | / | |||
Thoracotomy | 2 (8.7) | 2 (22.2) | 0 (0.0) | |
VATS | 21 (91.3) | 7 (77.8) | 14 (100.0) | |
Surgical Resection# | 0.106 | |||
Lobectomy | 19 (82.6) | 6 (66.7) | 13 (92.9) | |
Bi-Lobectomy | 4 (17.4) | 3 (33.3) | 1 (7.1) | |
Residual Tumor Cell, % (range)# | 0.015 | |||
45.9 (0–100) | 19.8 (0–55) | 63.3 (5–100) | ||
Pathologic Regression# | 0.034 | |||
pCR | 3 (13.0) | 3 (33.3) | 0 (0.0) | |
MPR | 5 (21.7) | 4 (44.4) | 1 (7.1) | |
Non-MPR | 18 (78.3) | 5 (55.6) | 13 (92.9) | |
